Antioxidant Supplementation in Patients With Kashin-Beck Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00376025 |
Recruitment Status : Unknown
Verified February 2008 by Innovative Humanitarian Solutions.
Recruitment status was: Recruiting
First Posted : September 14, 2006
Last Update Posted : February 22, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Kashin-Beck Disease | Dietary Supplement: Biological Antioxidant Supplementation | Phase 2 |
Current research regarding Kashin-Beck disease, (KBD) have identified dramatic deficiencies of both selenium and iodine in patients with this disease. Initial supplementation of these trace minerals provided no measurable benefit to the affected population. Research conducted by Innovative Humanitarian Solutions, suggests that such deficiencies may not be causal, but markers of an underlying condition of extreme oxidative stress brought on by the improper functioning of the Glutathione Peroxidase enzyme in synthesizing H202 during periods of critical cellular development, primarily in mesenchymal cell development.
The purpose of this trial is to determine the efficacy of antioxidant supplementation in aiding the Glutathione Peroxidase enzyme in its proper function and thereby reducing oxidative stress and enabling the uptake of selenium and iodine which are necessary for proper bone growth and development.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Study of the Effects of Antioxidant Supplementation in Patients Suffering From Kashin-Beck Disease |
Study Start Date : | July 2007 |
Estimated Primary Completion Date : | January 2009 |
Estimated Study Completion Date : | April 2009 |

- Dietary Supplement: Biological Antioxidant Supplementation
Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
- Score on FLACC or Word Graphic pain rating scale at 3, 6, 9 months [ Time Frame: One Year ]
- Increase in serum selenium concentrations at 6 months [ Time Frame: Six Months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 9 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically diagnosed patients with Kashin-Beck disease
Exclusion Criteria:
- less than 24 hours from admission to ICU
- Patients who are moribund
- Lack of commitment to program
- Absolute contraindication to enteral nutrients
- Severe acquired brain injury
- Pregnant or lactating patients
- Previous randomization in this study
- Enrollment in a related interventional study
- Child's class C liver disease Metastatic cancer with life expectancy < 6 months Seizure disorder requiring anticonvulsant medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376025
Contact: Jeff C Cokenour, B.S. | 832-863-5690 | jeff.cokenour@gmail.com | |
Contact: Don Heath, B.S. | donh@tamh.net |
China, Tibet | |
Lhasa Prefecture and surrounding villages | Recruiting |
Lhasa, Tibet, China, 850000 | |
Sub-Investigator: Don Heath |
Study Chair: | Richard Gunasekera, Ph.D. | University of Houston - Victoria | |
Principal Investigator: | Jeff C Cokenour, B.S. | Innovative Humanitarian Solutions | |
Principal Investigator: | Minh Han, M.D. | Innovative Humanitarian Solutions |
Publications:
Responsible Party: | Richard S. Gunasekera, Ph.D., Study Chair and P.I., University of Houston - Victoria |
ClinicalTrials.gov Identifier: | NCT00376025 |
Other Study ID Numbers: |
KB001 |
First Posted: | September 14, 2006 Key Record Dates |
Last Update Posted: | February 22, 2008 |
Last Verified: | February 2008 |
Kashin-Beck Disease Kashin-Beck Osteoarthropathy |
Kashin-Beck Disease Osteochondrodysplasias Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases |
Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs |